Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists

Neuron. 1995 Jan;14(1):169-75. doi: 10.1016/0896-6273(95)90251-1.

Abstract

Agonist binding to the inhibitory glycine receptor (GlyR) initiates the opening of a chloride-selective channel that modulates the neuronal membrane potential. Point mutations of the GlyR, substituting Arg-271 with either Leu or Gln, have been shown to underlie the inherited neurological disorder startle disease (hyperekplexia). We show that these substitutions result in the redistribution of GlyR single-channel conductances to lower conductance levels. Additionally, the binding of the glycinergic agonists beta-alanine and taurine to mutated GlyRs does not initiate a chloride current, but instead competitively antagonizes currents activated by glycine. These findings are consistent with mutations of Arg-271 resulting in the uncoupling of the agonist binding process from the channel activation mechanism of the receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arginine / genetics*
  • Binding, Competitive
  • Cell Line, Transformed
  • Chloride Channels / physiology
  • Electric Conductivity
  • Humans
  • Mutagenesis, Site-Directed*
  • Point Mutation
  • Receptors, Glycine / chemistry*
  • Receptors, Glycine / genetics
  • Receptors, Glycine / physiology
  • Structure-Activity Relationship
  • Strychnine / metabolism
  • Taurine / metabolism
  • Taurine / pharmacology*
  • Transfection
  • beta-Alanine / metabolism
  • beta-Alanine / pharmacology*

Substances

  • Chloride Channels
  • Receptors, Glycine
  • beta-Alanine
  • Taurine
  • Arginine
  • Strychnine